Compare MYFW & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | EDIT |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.8M | 233.3M |
| IPO Year | 2018 | 2016 |
| Metric | MYFW | EDIT |
|---|---|---|
| Price | $26.15 | $2.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.25 | $4.50 |
| AVG Volume (30 Days) | 31.3K | ★ 1.7M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 391.62 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $95,514,000.00 | $46,383,000.00 |
| Revenue This Year | $15.96 | N/A |
| Revenue Next Year | $13.77 | N/A |
| P/E Ratio | $20.41 | ★ N/A |
| Revenue Growth | ★ 19.92 | N/A |
| 52 Week Low | $17.10 | $0.91 |
| 52 Week High | $26.40 | $4.54 |
| Indicator | MYFW | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 73.24 | 41.37 |
| Support Level | $25.20 | $2.33 |
| Resistance Level | $26.40 | $2.61 |
| Average True Range (ATR) | 0.58 | 0.18 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 90.67 | 43.44 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.